A bispecific EGFR/MET antibody, called JNJ-61186372, has recently showed a potent inhibition of EGFR downstream effectors, resulting in tumor regression in NSCLC xenografts [136]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.